Related by context. All words. (Click for frequent words.) 73 AIM HIGH 73 RE LY ® 73 RE LY 72 multicenter randomized clinical 71 ACCOMPLISH 71 PRoFESS 71 ONTARGET R 71 placebo controlled clinical 70 prospective randomized controlled 70 phase IIIb 70 CARE HF 70 multicentre randomized 70 TRITON TIMI 70 BOLDER II 70 ALLHAT 70 TRANSCEND 69 BARI 2D 69 ACCORD Lipid 69 EchoCRT 69 Trandolapril 69 ExTRACT TIMI 69 phase IIa clinical 69 CLARITY TIMI 69 Intervention Effectiveness 69 randomized controlled clinical 69 Prostate Lung Colorectal 69 ADVANCE PD 68 ASTEROID 68 placebo controlled Phase III 68 ACRIN 68 randomized Phase III 68 Intervention Trial GAIT 68 Valsartan 68 telmisartan 68 ToGA 68 Ovarian Cancer Screening 68 PROactive study 68 confirmatory clinical 68 International Verapamil SR 68 RE MODEL 68 double blinded randomized 67 prospective multicenter 67 randomized clinical 67 phase IIb clinical 67 VADT 67 Randomized Evaluation 67 BCIRG 67 NO# [002] 67 Phase Ib clinical 67 Randomized controlled 67 multicenter prospective 67 REALITY Trial 67 STRIDE PD 67 LUMINATE 67 CHARM Added 67 SCD HeFT 67 Multicenter Automatic Defibrillator Implantation 67 active comparator 67 SPARCL 67 Val HeFT 67 ASCEND HF 67 HPTN 67 substudy 67 BOLDER 67 APEX PD 66 ATACAND 66 MERLIN TIMI 66 Digital Mammographic Imaging 66 multicenter placebo controlled 66 placebo controlled randomized 66 multicenter clinical 66 candesartan cilexetil 66 multicenter randomized controlled 66 evaluating Actimmune 66 Telmisartan 66 sunitinib malate 66 Carotid Revascularization Endarterectomy vs. 66 landmark ATHENA 66 HOPE TOO 66 MADIT 66 prospective randomized multicenter 66 BRIM3 66 PFO migraine 66 Prostate Cancer Prevention 66 LUX Lung 66 Clinical Antipsychotic Trials 66 riociguat 66 HORIZONS AMI 66 HF ACTION 66 MEND CABG 65 Cholesterol Levels SPARCL 65 Stenting Trial CREST 65 Aggressive Reduction 65 fosbretabulin 65 Phase IIIb 65 multicentre 65 AVERROES 65 ARBITER 6 65 REACH Registry 65 randomized multicenter 65 NCT# ClinicalTrials.gov 65 multicentre prospective 65 Betaferon ® 65 ROCKET AF 65 TG MV 65 Phase IIB 65 Phase IIIb clinical 65 Phase Ib II 65 Prospective Randomized 65 SPIRIT IV 65 atorvastatin Lipitor 65 ENDEAVOR IV 65 CURRENT OASIS 7 65 CALGB 65 placebo controlled Phase 65 nonrandomized 65 prospective randomized placebo 65 ECASS 65 PERSEUS 65 CHAMPION PCI 65 NCCTG 65 CHARISMA trial 65 ACTIVE W 65 HeFT 65 multicenter trials 65 multicenter randomized 64 GISSI 64 Left Ventricular Dysfunction 64 MADIT CRT 64 SWOG 64 EURIDIS 64 tipranavir 64 EVEREST II 64 multicenter Phase II 64 evaluating tivozanib 64 AVADO 64 Acute Ischemic Stroke 64 Phase III randomized 64 TAXUS VI 64 Asthma Intervention 64 TAXUS ATLAS 64 OLYMPIA registry 64 multicentre randomized controlled 64 PRECISE 64 TMC# C# 64 phase IIa 64 ILLUMINATE 64 iPrEx 64 MIST II 64 thorough QT 64 angiotensin receptor blocker ARB 64 CATIE AD 64 blinded randomized placebo controlled 64 CIMZIA TM certolizumab pegol 64 EDEMA3 64 APTIVUS 64 Candesartan 64 NEVO RES 64 multicenter multinational 64 subanalysis 64 irbesartan 64 Prostate AdenoCarcinoma Treatment 64 multicenter randomized placebo controlled 64 Phase III VISTA 64 Ovarian PLCO Cancer 64 randomized controlled multicenter 64 TAXUS IV 64 rosuvastatin Crestor 64 Sibutramine Cardiovascular Outcomes 64 CAMMS# 63 NICE SUGAR 63 REMINYL ® 63 BENICAR HCT 63 Phase IIb III 63 DAPT Study 63 Screening Trial DMIST 63 HMG CoA reductase inhibitors 63 HYVET 63 fostamatinib 63 EORTC 63 Evaluation WISE 63 IMPROVE HF 63 phase IIb 63 Intervention Effectiveness CATIE 63 NATRECOR ® 63 Meta analyzes 63 prospective observational 63 CALGB # [002] 63 tanespimycin 63 multicenter Phase III 63 CAPRISA 63 brivaracetam 63 NATRECOR R 63 TRANSFORMS 63 Screening Trial 63 sorafenib Nexavar 63 ENESTnd 63 Phase III placebo controlled 63 Adenoma Prevention 63 Phase 1a clinical 63 phase III ACCLAIM 63 Acute Decompensated Heart Failure 63 EXPLORE Xa 63 blinded randomized 63 Rosuvastatin 63 rosuvastatin #mg 63 HCV SPRINT 63 Fondaparinux 63 CIMZIA ™ 63 prospective multicentre 63 ENGAGE AF TIMI 63 PRADAXA 63 STENT 63 elotuzumab 63 pertuzumab 63 DIRECT Trial 63 prucalopride 63 DAPT 63 CHARISMA 63 Phase III multicenter 63 ACUITY trial 63 CALERIE 63 ezetimibe simvastatin 63 Pirfenidone 63 CYPHER Stent 63 Carvedilol 63 ARCOXIA 63 teriflunomide 63 CONQUER OB 63 efficacy tolerability 63 fenofibric acid 63 Glucosamine Chondroitin Arthritis 63 PROVE IT 63 subgroup analyzes 63 AIR CF2 63 RIO Lipids 63 valsartan Diovan 63 JAK Inhibitor 63 PREVENT IV 63 Phase 1b clinical 63 muraglitazar 63 Platelet Inhibition 63 Acute Myocardial Infarction 63 ENDEAVOR III 62 randomized Phase IIb 62 double blinded placebo 62 PARTNER Trial 62 Randomised 62 oral FTY# 62 Initiated Phase 62 randomized blinded 62 placebo controlled multicenter 62 Randomized Clinical Trial 62 multicenter 62 INTERHEART study 62 Refractory Angina 62 Long Lesion 62 PLCO 62 ASPIRE HIGHER 62 clinical pharmacology studies 62 prospective nonrandomized 62 BRIM2 62 registrational Phase 62 Pioglitazone 62 valsartan 62 SANTE 62 Sorafenib HCC Assessment 62 Antihypertensive 62 Traficet EN 62 Spine Patient Outcomes 62 SABCS 62 cardio renal 62 Phase III Pivotal 62 Phase 2b kidney transplant 62 Prospective Multicenter 62 Multicenter 62 phase Ib 62 ENDEAVOR clinical 62 Tipranavir 62 posaconazole 62 AEGR 62 interferon gamma 1b 62 Phase #b/#a 62 CANCIDAS 62 UPLYSO 62 GFT# 62 vildagliptin 62 ZD# [001] 62 Ranolazine 62 Cardiovascular Outcomes 62 NSABP 62 Aflibercept 62 AVASTIN 62 reslizumab 62 CoFactor 62 Phase #/#a 62 multicenter Phase 62 NCCTG N# 62 Celebrex celecoxib 62 ASSERT 62 number NCT# ClinicalTrials.gov 62 Lipid Lowering Treatment 62 AVANDIA 62 Phase III Clinical Trials 62 Acute Coronary Syndromes 62 celecoxib Celebrex 62 randomized controlled clinical trials 62 PRE SURGE 62 6R BH4 62 boosted protease inhibitor 62 TLK# 62 axitinib 62 Aplidin R 62 pharmacokinetic PK study 62 MADIT II 62 tarenflurbil 62 Truvada tablets 62 Pivotal Phase III 62 lapatinib Tykerb 62 REG1 62 MAGE A3 ASCI 62 viral kinetic 62 CBLC# 62 ENDEAVOR II 62 AZILECT R 62 Celecoxib APC trial 62 TYKERB 62 Aggressive Drug Evaluation 62 Tekturna HCT 62 placebo controlled studies 61 Health Initiative WHI 61 multicentre randomized double 61 EINSTEIN DVT 61 oral rivaroxaban 61 candesartan 61 ReoPro 61 tocilizumab 61 Serious Adverse Events 61 CINQUIL 61 lumiracoxib 61 enzastaurin 61 PSN# [002] 61 Secondary efficacy endpoints 61 PROTEGE 61 ANCHOR trial 61 ARIXTRA 61 JAK inhibitor 61 Phase Ib IIa 61 VICTOR E3 61 aripiprazole Abilify 61 olaparib 61 AVOREN 61 randomized controlled 61 Diabetes ACCORD 61 pivotal bioequivalence 61 rosuvastatin 61 Rasilez Tekturna 61 Deforolimus 61 Vimpat R 61 AIR2 Trial 61 Dalbavancin 61 MICARDIS ® 61 pharmacodynamic effects 61 RhuDex 61 RE LY trial 61 COPAXONE R 61 Zenvia Phase III 61 multicenter phase 61 Randomized Phase III 61 CATIE 61 GOUT 61 GAMMAGARD 61 EDEMA4 61 Phase 1b trial 61 designated HVTN 61 darunavir ritonavir 61 ATTRACT 61 KRN# 61 Pivotal Trial 61 Zemplar Capsules 61 everolimus eluting stent 61 RIO Diabetes 61 Protelos 61 SIMCOR 61 bosentan 61 IMPROVE IT 61 Interferon beta 1a 61 INTEGRILIN 61 PROactive Study 61 ThermoDox ® clinical 61 Catena ® 61 PRESEPT 61 lacosamide 61 assessing T DM1 61 afatinib 61 noninferiority 61 placebo controlled clinical trials 61 Thrombolysis 61 pioglitazone HCl 61 Welchol 61 ADMIRE HF 61 thiazolidinedione TZD 61 APPRAISE 61 RESOLUTE clinical 61 ADHERE 61 rNAPc2 61 SPIRIT FIRST 61 PRECiSE 61 tolvaptan 61 investigational protease inhibitor 61 Ezetimibe 61 CLL8 61 topiramate Topamax 61 Apixaban 61 trastuzumab Herceptin 61 galiximab 61 Zoraxel 61 ACTEMRA 61 CERVARIX 61 STICH trial 61 Edge STudy 61 ILLUSTRATE 61 ELCAP 61 Randomized Double blind 61 Raloxifene Evaluation MORE 61 EXPAREL ™ 61 ORAL Sync 61 Betaferon R 61 masked placebo controlled 61 ZACTIMA 61 MGd 61 ataluren 61 Cardiac Allograft Rejection 61 gefitinib Iressa 61 Ophena 61 unfractionated heparin UFH 61 CABANA 61 LymphoStat B 61 multicenter randomized double 61 glatiramer acetate 61 Medtronic CoreValve 61 ONCONASE R 61 Vasogen Celacade 61 Phase III randomized controlled 61 ritonavir boosted 61 placebo controlled 61 miconazole Lauriad ® 61 selenium supplementation 61 CIMZIA TM 61 NAVIGATOR 61 Phase 2b clinical 61 Afatinib 61 colesevelam HCl 61 Tracleer R 61 PRIMO CABG 61 UNLOAD 61 eprotirome 61 blinded randomized controlled 61 Intervention Trial 60 Zometa zoledronic acid 60 RG# ITMN 60 FASLODEX 60 Mycophenolate Mofetil 60 relapsed MM 60 Epirubicin 60 Adalimumab 60 diabetic neuropathic pain 60 POISE 60 bazedoxifene conjugated estrogens 60 controlled multicenter 60 Taxotere ® 60 Tarceva TM 60 atrasentan 60 Heart Failure Trial 60 Azedra 60 prospective observational studies 60 mycophenolate mofetil 60 azilsartan medoxomil 60 Phase IIIb study 60 STICH 60 clevidipine 60 Cotavance 60 dabigatran etexilate 60 DU #b 60 prospectively defined 60 ganetespib 60 ONGLYZA 60 LibiGel Phase III 60 Phase 2a trial 60 longitudinal cohort study 60 Olmesartan 60 IRESSA 60 oral Xeloda 60 ARIMIDEX 60 Phase #b/#a clinical 60 GRAVITAS 60 Aliskiren 60 Tanespimycin 60 YONDELIS 60 prospective randomized 60 prasugrel Effient 60 oral deforolimus 60 RADIANT 60 AZOR 60 Xelox 60 trials RCTs 60 ASSERT trial 60 lorcaserin Phase 60 ACTEMRA TM 60 Pulmonary Arterial Hypertension 60 fluvastatin 60 Phase 2b Study 60 Sapacitabine 60 tasocitinib 60 RenalGuard System TM 60 MEVACOR 60 atherothrombotic disease 60 Phase III Clinical Trial 60 SPIRIT III 60 UPLIFT 60 Celsentri Selzentry 60 Teriflunomide 60 Myocardial Infarction 60 retrospective cohort 60 TASKi2 60 Val MARC 60 IMA# 60 Ramipril 60 intensive lipid lowering 60 First Patient Enrolled 60 Patient Outcomes 60 randomized placebo controlled 60 CHAMPION PLATFORM 60 Medidur TM FA 60 olmesartan 60 ongoing Phase IIIb 60 angiotensin receptor blockers 60 CTRC AACR San Antonio 60 prospective multicenter randomized 60 carotid artery stenting CAS 60 ADAGIO study 60 strontium ranelate 60 PROactive 60 Degarelix 60 lenalidomide Revlimid R 60 Women Ischemia Syndrome 60 HuMax EGFr 60 ZYBRESTAT fosbretabulin 60 YERVOY 60 label multicenter 60 ORENCIA ® 60 Randomized Controlled Trials 60 CYPHER ® Stent 60 neratinib 60 Alpha Tocopherol Beta Carotene 60 antioxidant supplementation 60 LCP AtorFen 60 Outpatient Setting 60 Controlled Trial 60 MYCAMINE 60 arzoxifene 60 Randomized Phase 60 GW# [003] 60 Ophena TM 60 ISENTRESS 60 cilostazol 60 COPERNICUS 60 sertraline Zoloft 60 mg BID dose 60 Gemzar ® 60 Sirolimus eluting Coronary Stent 60 Dual Antiplatelet Therapy 60 Unstable Angina 60 Renal Cell Carcinoma RCC 60 randomized multicenter trial 60 XIENCE V Everolimus Eluting 60 AIR CF1 60 bevacizumab Avastin 60 ISEL 60 Bucindolol 60 NSABP B 60 Fabry Disease 60 dose escalation clinical 60 CAPRIE 60 Tiotropium 60 Dapagliflozin 60 lexidronam injection 60 Clolar ® 60 Trial PCPT 60 RE COVER 60 Medidata Designer 60 blind randomized controlled 60 atacicept 60 evaluating Vectibix 60 Pertuzumab 60 Atacand 60 TAXUS Stent 60 Phase Forward InForm 60 STEEPLE 60 LEXIVA r 60 Immune Tolerance Network 60 See CLINICAL PHARMACOLOGY 60 Meets Primary Endpoint 60 Glucosamine chondroitin Arthritis 60 HCV RESPOND 2 60 ticagrelor Brilinta 60 ON #.Na 60 Thorough QT 60 Xanafide 60 Dabigatran 60 ticagrelor 60 STEP BD 60 sildenafil Viagra 60 ULORIC 60 TIMI Study Group 60 senicapoc 60 vidofludimus 60 randomized multicentre 60 Moxifloxacin 60 AZILECT ® 60 LEUKINE 60 Multiple Ascending Dose 60 antihypertensive therapy 60 pharmacokinetic PK 60 beta carotene supplementation 60 phase IIb study 60 abatacept 60 ramipril 60 ClinicalTrials.gov 60 Glypromate 60 TELCYTA 60 Inhalation Solution 60 BioMarck 60 RTOG 60 First Patient Dosed 59 DDW ® 59 SUTENT ® 59 Study ADCS 59 mapatumumab 59 trodusquemine 59 CYCLOSET 59 ICON7 59 CALGB # [001] 59 paroxetine Paxil 59 MKC# MKC# PP 59 Severe Sepsis 59 trastuzumab emtansine T DM1 59 EmbraceAC 59 Vascugel ® 59 ZOLINZA 59 CRESTOR #mg 59 Trial NLST 59 CaPSURE 59 icatibant 59 AVAPRO 59 evaluating REVLIMID 59 APEX AMI trial 59 iniparib 59 REGARDS 59 ORMD 59 pharmacokinetics PK 59 velafermin 59 Radiation Therapy Oncology 59 PRT# 59 eplerenone 59 GISSI HF 59 WHIMS 59 PROSTVAC TM 59 undergoing elective percutaneous 59 prelicensure 59 Tyrima 59 randomized controlled Phase 59 SWiTCH 59 GSK# [001] 59 pioglitazone Actos 59 Topline Results 59 Pafuramidine 59 GetGoal Phase III 59 Virtual Histology 59 ABCSG 59 tramiprosate Alzhemed TM 59 Phase III ADT 59 Proellex TM 59 Teplizumab 59 Polyp Prevention Trial 59 ALTTO 59 Corus CAD 59 deforolimus 59 tesmilifene 59 PREDICTIVE 59 Coversyl 59 COR Diabetes 59 macrovascular disease 59 Multicenter Phase 59 PREVAIL 59 Ticagrelor 59 metastatic HRPC 59 sulodexide 59 novel VDA molecule 59 UroVysion 59 TREDAPTIVE 59 ID NCT# 59 pegylated interferon alfa 2b 59 desvenlafaxine succinate 59 ACOMPLIA R 59 CombAT 59 IMPACT IMmunotherapy 59 Primary endpoints 59 Stedivaze 59 multicentre study 59 TASKi3 59 Hepatotoxicity 59 placebo controlled trials 59 FDA Investigational Device 59 phase Ib clinical 59 SEROQUEL 59 IIa clinical 59 INSPIRE Trial Phase III 59 Varespladib 59 Lp PLA 2 59 controlled multicenter Phase 59 Long Term Efficacy 59 Pivotal Phase 59 CaPre TM 59 Cardiotoxicity 59 Investigator Initiated 59 APTIVUS r 59 darapladib 59 RELOVAIR ™ 59 blind randomized 59 Phase 1b clinical trials 59 fenretinide 59 donepezil Aricept 59 esomeprazole Nexium 59 Phase 2a clinical 59 dose atorvastatin 59 Angiolix 59 docetaxel Taxotere ® 59 lipid lowering drugs 59 Zolinza 59 Exforge HCT 59 Alfimeprase 59 NEVO 59 Alzheimer Disease Cooperative 59 PIX# [002] 59 TRO# 59 ofatumumab HuMax CD# 59 cobiprostone 59 Anacetrapib 59 BENICAR 59 inhaled anticholinergics 59 Fulvestrant 59 HORIZONS AMI trial 59 direct thrombin inhibitors 59 selective androgen receptor modulator 59 Tocilizumab 59 EQUIP OB 59 APEX AMI 59 Randomized Controlled 59 anastrozole Arimidex 59 alvespimycin 59 ACEIs 59 anti arrhythmic 59 secondary efficacy endpoints 59 Elocalcitol 59 anti arrhythmic drug 59 nab paclitaxel 59 ezetimibe 59 fenofibrate 59 Group RTOG 59 RESIST 59 Androxal TM 59 ARBITER 59 acyclovir Lauriad R 59 Aortic Stenosis 59 Ambrisentan 59 ARIXTRA R 59 Cethromycin 59 MoxDuo IR 59 vorinostat 59 Arzerra TM 59 sunitinib 59 Phase III AFFIRM 59 pomalidomide 59 Elagolix 59 PRTX 59 Bowel Project NSABP 59 cediranib 59 Phase IIA 59 observational cohort 59 erlotinib Tarceva ® 59 Nesiritide 59 LITHE 59 citalopram Celexa 59 Pemetrexed 59 sitagliptin 59 rosiglitazone 59 Combo Stent 59 NCT# 59 LYSTEDA 59 PERISCOPE 59 Anturol TM 59 ALN HPN 59 clinical trial 59 MYTHOS trial 59 adalimumab 59 reboxetine 59 CUSTOM II 59 crizotinib PF # 59 ORAL Solo 59 FOLOTYN ® 59 skin sterol 59 Dasatinib 59 Orazol 59 TRILIPIX 59 VerifyNow 59 Multaq R 59 Oral Fingolimod 59 ® pioglitazone HCl 59 protease inhibitor PI 59 Perindopril 59 perindopril 59 deferiprone 59 alendronate Fosamax 59 SUCCEED trial 59 ibandronate 59 TDF FTC 59 INTELENCE 59 Doxil ® 59 Double Blind Placebo 59 Bivalirudin 59 INCB# [001] 59 randomized multicenter Phase III 59 Pyridorin 59 FOLFOX6 chemotherapy regimen 59 ularitide 59 catheter occlusion 59 Phase Ib study 59 ALTACE 59 Pharmacokinetic 59 GRAVITAS trial 59 RSD# oral 59 COMFORT II 59 PRIMO CABG2 59 FIX HF 5 59 Randomized Double Blind 59 pitavastatin 59 preclinical efficacy 59 bevacizumab Avastin ® 59 PREVU x 59 registrational 59 dose escalation phase 59 Percutaneous Coronary Intervention 58 blind randomized placebo 58 Phase III randomized placebo 58 ABC/3TC 58 longitudinal observational study 58 National Surgical Adjuvant 58 Diabetic Macular Edema 58 DASISION 58 NP2 Enkephalin 58 dyslipidaemia 58 prospective observational cohort 58 Cloretazine 58 IL# PE#QQR 58 Avanafil 58 HIVNET 58 Aptivus ® 58 BETAS 58 VaD 58 Bioequivalence 58 treatment naive genotype 58 Triolex 58 PrevOnco 58 Clinical Trial Data 58 dutasteride 58 ACCORD Eye 58 multicenter randomized Phase III 58 Phase III clinical 58 teriparatide 58 Ixempra 58 Schizophrenia Treatment 58 aldosterone antagonists 58 Raptiva r 58 ORACLE MS 58 Amplimexon 58 AOD# [002] 58 Phase Ib Clinical Trial 58 LibiGel ® 58 tipifarnib 58 pharmacodynamic properties 58 PREZISTA r 58 Phase 2b Clinical Trial 58 DOXIL 58 Preclinical Study 58 sipuleucel T 58 ENDEAVOR 58 Cardiac Resynchronization 58 Perforomist Inhalation Solution 58 cinacalcet 58 vicriviroc 58 Muraglitazar 58 Cardiovascular Risk 58 Neoadjuvant 58 PHASE III 58 Surgical Treatment 58 visilizumab 58 Phase IIa trials 58 ziprasidone Geodon 58 enalapril 58 WHEL 58 Phase III ThermoDox 58 FREEDOMS 58 prospective longitudinal 58 phase III SIMPADICO 58 Phase IIb clinical 58 CardioFit 58 ADHF 58 Eluting Stent 58 Urocortin 2 58 iPrEx study 58 lasofoxifene 58 ACCLAIM 58 eltrombopag 58 HALTS 58 Neulasta ® 58 Cancer Prevention ATBC 58 ongoing Phase 1b 58 eptifibatide 58 PreCISe 58 TAXUS TM 58 balsalazide tablet 58 macrovascular 58 LY# [003] 58 pregabalin Lyrica 58 Cetrorelix 58 XELOX 58 XL# XL# XL# 58 Zestra R 58 HyACT 58 Quinamed 58 blinded placebo controlled 58 ARCALYST ® rilonacept 58 MEND CABG II 58 SCH # 58 Liraglutide Effect 58 Aplidin 58 BioNumerik 58 tenofovir emtricitabine 58 oral ridaforolimus 58 lumiliximab 58 pravastatin Pravachol 58 docetaxel Taxotere R 58 Targretin 58 Safinamide 58 carotid artery stenting 58 RECORD1 58 chlorthalidone 58 FOLPI 58 metastatic hormone refractory 58 pharmacodynamics 58 cathepsin K inhibitor 58 Ziprasidone 58 multicenter study 58 INC# 58 pain palliation 58 Relapsing Multiple Sclerosis 58 HGS# 58 Daclizumab 58 paroxetine Seroxat 58 dose escalation Phase 58 AA Amyloidosis 58 REVIVE Diabetes 58 rALLy clinical trial 58 Eluting Coronary Stent System 58 CYPHER R Sirolimus eluting 58 rosiglitazone Avandia 58 sorafenib tablets 58 CLORETAZINE TM VNP#M 58 Rasilez ® 58 safinamide 58 Tolvaptan 58 Blinatumomab 58 SORT OUT 58 Mylotarg 58 cerivastatin 58 adalimumab Humira 58 raltegravir 58 metaglidasen 58 DermaVir Patch 58 flurpiridaz F 58 lipid lowering 58 AREDS 58 aliskiren 58 Exelixis XL# 58 VITAL Trial 58 BRILINTA 58 bicifadine 58 Subgroup Analysis